Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
Protagenic Therapeutics, Inc.\new (PTIX)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
4.33
|
M
| |
-64
|
% ROE
|
| Market cap: |
$4.3
|
k
| |
-67
|
% ROIC
|
|
Net cash:
|
$6.04
|
M
| |
$1.40
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($3.5)
|
M
| |
|
|
|
EBIT
|
($3.5)
|
M
| |
|
|
| EPS |
($0.64)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | 0.4 | 0.0 |
| Revenue growth | | | | | -100.0% | 469.4% | | -100.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | -0.4 | 0.0 |
| Gross margin | | | | | | 100.0% | -100.0% | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 1.6 | 1.1 | 0.7 | 0.8 | 0.9 | 0.7 | | 0.5 |
| General and administrative | 2.0 | 3.0 | 1.9 | 1.3 | 1.4 | 1.6 | 1.4 | 0.6 |
| EBIT | -3.6 | -4.1 | -2.6 | -1.7 | -2.6 | -2.3 | -1.8 | -1.0 |
| EBIT margin | | | | | | -95.6% | -437.8% | |
| Pre-tax income | -3.6 | -4.5 | -2.5 | -1.8 | -2.6 | -2.3 | -2.3 | -1.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -3.6 | -4.5 | -2.5 | -1.8 | -2.6 | -2.3 | -2.3 | -1.0 |
| Net margin | | | | | | -95.0% | -544.6% | |
| |
| Diluted EPS | ($0.82) | ($1.23) | ($0.25) | ($0.17) | ($0.25) | ($0.22) | ($0.43) | ($0.15) |
| Shares outstanding (diluted) | 4.3 | 3.7 | 10.3 | 10.3 | 10.3 | 10.3 | 5.3 | 6.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|